Primary lung graft dysfunction

INTRODUCTION

Primary graft dysfunction (PGD) after lung transplantation represents a multifactorial injury to the transplanted lung that develops in the first 72 hours after transplantation; it is variously referred to as "ischemia-reperfusion injury", "early graft dysfunction", and "reimplantation edema." PGD is characterized by severe hypoxemia, lung edema, and the radiographic appearance of diffuse pulmonary opacities without other identifiable cause. The typical pathologic pattern of PGD is diffuse alveolar damage.

Despite significant advances in organ preservation, surgical technique, and perioperative care, PGD is responsible for significant morbidity and mortality after lung transplantation [1-4].

The pathophysiology, risk factors, diagnosis, grading, and strategies to prevent PGD are reviewed here. Postoperative management following lung transplantation, evaluation of acute lung transplant rejection, and immunosuppression following lung transplantation are reviewed separately. (See "Lung transplantation: Procedure and postoperative management" and "Evaluation and treatment of acute lung transplant rejection" and "Induction immunosuppression following lung transplantation".)

EPIDEMIOLOGY

The incidence of PGD is reported to be in the range of 10 to 25 percent; it is the leading cause of early death after lung transplantation [1-6]. Survivors of PGD tend to have a longer duration of mechanical ventilation, longer hospital stay, and lower lung function over time [1]. As an example, a retrospective study of 255 lung transplant procedures found that recipients with severe PGD (table 1) versus those without had a 30 day mortality of 63 versus 9 percent and duration of mechanical ventilation of 15 versus 1 day(s) [2].

PATHOPHYSIOLOGY

PGD reflects the summation of injury inflicted on the donor lung by the transplant process (retrieval, preservation, implantation, and reperfusion) and by other factors such as acid aspiration, pneumonia, and microtrauma from mechanical ventilation [7] (figure 1). Recipient factors also play a role in the development of PGD. For example, recipients with pulmonary fibrosis and primary pulmonary hypertension have higher incidence of PGD compared with patients with emphysema.

                                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Apr 23, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Christie JD, Bavaria JE, Palevsky HI, et al. Primary graft failure following lung transplantation. Chest 1998; 114:51.
  2. Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124:1232.
  3. King RC, Binns OA, Rodriguez F, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69:1681.
  4. Christie JD, Sager JS, Kimmel SE, et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127:161.
  5. Khan SU, Salloum J, O'Donovan PB, et al. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response. Chest 1999; 116:187.
  6. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005. J Heart Lung Transplant 2005; 24:956.
  7. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167:490.
  8. de Perrot M, Bonser RS, Dark J, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 2005; 24:1460.
  9. Fisher AJ, Donnelly SC, Hirani N, et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001; 163:259.
  10. Kaneda H, Waddell TK, de Perrot M, et al. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006; 6:544.
  11. Tremblay LN, Yamashiro T, DeCampos KN, et al. Effect of hypotension preceding death on the function of lungs from donors with nonbeating hearts. J Heart Lung Transplant 1996; 15:260.
  12. Rostron AJ, Avlonitis VS, Cork DM, et al. Hemodynamic resuscitation with arginine vasopressin reduces lung injury after brain death in the transplant donor. Transplantation 2008; 85:597.
  13. Avlonitis VS, Wigfield CH, Golledge HD, et al. Early hemodynamic injury during donor brain death determines the severity of primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7:83.
  14. Thabut G, Mal H, Cerrina J, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med 2005; 171:786.
  15. Fiser SM, Kron IL, Long SM, et al. Influence of graft ischemic time on outcomes following lung transplantation. J Heart Lung Transplant 2001; 20:1291.
  16. Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant 1999; 18:425.
  17. Fisher AB, Al-Mehdi AB, Muzykantov V. Activation of endothelial NADPH oxidase as the source of a reactive oxygen species in lung ischemia. Chest 1999; 116:25S.
  18. De Perrot M, Sekine Y, Fischer S, et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 2002; 165:211.
  19. Covarrubias M, Ware LB, Kawut SM, et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7:2573.
  20. Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998; 102:919.
  21. Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180:1010.
  22. Ivey CL, Williams FM, Collins PD, et al. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8. J Clin Invest 1995; 95:2720.
  23. Sato Y, Hogg JC, English D, van Eeden SF. Endothelin-1 changes polymorphonuclear leukocytes' deformability and CD11b expression and promotes their retention in the lung. Am J Respir Cell Mol Biol 2000; 23:404.
  24. Zwacka RM, Zhang Y, Halldorson J, et al. CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 1997; 100:279.
  25. Eppinger MJ, Jones ML, Deeb GM, et al. Pattern of injury and the role of neutrophils in reperfusion injury of rat lung. J Surg Res 1995; 58:713.
  26. Fiser SM, Tribble CG, Long SM, et al. Lung transplant reperfusion injury involves pulmonary macrophages and circulating leukocytes in a biphasic response. J Thorac Cardiovasc Surg 2001; 121:1069.
  27. Eppinger MJ, Deeb GM, Bolling SF, Ward PA. Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol 1997; 150:1773.
  28. de Perrot, M, Young, K, Imai, Y, et al. Involvement of donor T cells in the regulation of ischemia-reperfusion injury during lung transplantation [abstract]. J Heart Lung Transplant 2002; 21:163.
  29. Whitson BA, Nath DS, Johnson AC, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006; 131:73.
  30. Oto T, Excell L, Griffiths AP, et al. The implications of pulmonary embolism in a multiorgan donor for subsequent pulmonary, renal, and cardiac transplantation. J Heart Lung Transplant 2008; 27:78.
  31. Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187:527.
  32. Barr ML, Kawut SM, Whelan TP, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers. J Heart Lung Transplant 2005; 24:1468.
  33. Fang A, Studer S, Kawut SM, et al. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2011; 139:782.
  34. Bobadilla JL, Love RB, Jankowska-Gan E, et al. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008; 177:660.
  35. Bharat A, Saini D, Steward N, et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg 2010; 90:1094.
  36. Tiriveedhi V, Gautam B, Sarma NJ, et al. Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations. J Heart Lung Transplant 2013; 32:807.
  37. Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24:1454.
  38. Oto T, Griffiths AP, Levvey BJ, et al. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg 2006; 132:140.
  39. Christie JD, Bellamy S, Ware LB, et al. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2010; 29:1231.
  40. Arcasoy SM, Fisher A, Hachem RR, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant 2005; 24:1483.
  41. Prekker ME, Herrington CS, Hertz MI, et al. Early Trends in PaO(2)/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction. Chest 2007; 132:991.
  42. Christie, JD, Ahya, VN, Sager, JS, et al. ISHLT PGD grade predicts differential mortality following lung transplantation. J Heart Lung Transplant 2005; 24 Suppl 2:S71.
  43. Masson E, Stern M, Chabod J, et al. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant 2007; 26:642.
  44. Pierre AF, DeCampos KN, Liu M, et al. Rapid reperfusion causes stress failure in ischemic rat lungs. J Thorac Cardiovasc Surg 1998; 116:932.
  45. Clark SC, Sudarshan C, Khanna R, et al. Controlled reperfusion and pentoxifylline modulate reperfusion injury after single lung transplantation. J Thorac Cardiovasc Surg 1998; 115:1335.
  46. Bhabra MS, Hopkinson DN, Shaw TE, et al. Controlled reperfusion protects lung grafts during a transient early increase in permeability. Ann Thorac Surg 1998; 65:187.
  47. Halldorsson A, Kronon M, Allen BS, et al. Controlled reperfusion after lung ischemia: implications for improved function after lung transplantation. J Thorac Cardiovasc Surg 1998; 115:415.
  48. Chiang CH, Wu K, Yu CP, et al. Protective agents used as additives in University of Wisconsin solution to promote protection against ischaemia-reperfusion injury in rat lung. Clin Sci (Lond) 1998; 95:369.
  49. Chiang CH, Wu K, Yu CP, et al. Hypothermia and prostaglandin E(1) produce synergistic attenuation of ischemia-reperfusion lung injury. Am J Respir Crit Care Med 1999; 160:1319.
  50. Naka Y, Roy DK, Liao H, et al. cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ Res 1996; 79:773.
  51. Levin G, Duffin KL, Obukowicz MG, et al. Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J 2002; 365:489.
  52. de Perrot M, Fischer S, Liu M, et al. Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti-inflammatory cytokines. Transplantation 2001; 72:1505.
  53. Wittwer T, Franke UF, Ochs M, et al. Inhalative pre-treatment of donor lungs using the aerosolized prostacyclin analog iloprost ameliorates reperfusion injury. J Heart Lung Transplant 2005; 24:1673.
  54. Meade M, Granton JT, Matte-Martyn A, et al. A randomized trial of inhaled nitric oxide to prevent reperfusion injury following lung transplantation. J Heart Lung Transplant 2001; 20:254.
  55. Botha P, Jeyakanthan M, Rao JN, et al. Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2007; 26:1199.
  56. Perrin G, Roch A, Michelet P, et al. Inhaled nitric oxide does not prevent pulmonary edema after lung transplantation measured by lung water content: a randomized clinical study. Chest 2006; 129:1024.
  57. Date H, Triantafillou AN, Trulock EP, et al. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996; 111:913.
  58. Kemming GI, Merkel MJ, Schallerer A, et al. Inhaled nitric oxide (NO) for the treatment of early allograft failure after lung transplantation. Munich Lung Transplant Group. Intensive Care Med 1998; 24:1173.
  59. Shargall Y, Guenther G, Ahya VN, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J Heart Lung Transplant 2005; 24:1489.
  60. Adatia I, Lillehei C, Arnold JH, et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994; 57:1311.
  61. Fischer S, Bohn D, Rycus P, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: analysis of the Extracorporeal Life Support Organization (ELSO) registry. J Heart Lung Transplant 2007; 26:472.
  62. Dahlberg PS, Prekker ME, Herrington CS, et al. Medium-term results of extracorporeal membrane oxygenation for severe acute lung injury after lung transplantation. J Heart Lung Transplant 2004; 23:979.
  63. Bermudez CA, Adusumilli PS, McCurry KR, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: long-term survival. Ann Thorac Surg 2009; 87:854.
  64. Meyers BF, Sundt TM 3rd, Henry S, et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000; 120:20.
  65. Fiser SM, Kron IL, McLendon Long S, et al. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant 2001; 20:631.
  66. Hartwig MG, Walczak R, Lin SS, Davis RD. Improved survival but marginal allograft function in patients treated with extracorporeal membrane oxygenation after lung transplantation. Ann Thorac Surg 2012; 93:366.
  67. Glassman LR, Keenan RJ, Fabrizio MC, et al. Extracorporeal membrane oxygenation as an adjunct treatment for primary graft failure in adult lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110:723.
  68. Diaz-Guzman E, Davenport DL, Zwischenberger JB, Hoopes CW. Lung function and ECMO after lung transplantation. Ann Thorac Surg 2012; 94:686.
  69. Ware LB, Fang X, Wang Y, et al. Selected contribution: mechanisms that may stimulate the resolution of alveolar edema in the transplanted human lung. J Appl Physiol (1985) 2002; 93:1869.
  70. Ochs M, Nenadic I, Fehrenbach A, et al. Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion. Am J Respir Crit Care Med 1999; 160:718.
  71. Andrade RS, Solien EE, Wangensteen OD, et al. Surfactant dysfunction in lung preservation. Transplantation 1995; 60:536.
  72. Hohlfeld JM, Strüber M, Ahlf K, et al. Exogenous surfactant improves survival and surfactant function in ischaemia-reperfusion injury in minipigs. Eur Respir J 1999; 13:1037.
  73. Koletsis E, Chatzimichalis A, Fotopoulos V, et al. Donor lung pretreatment with surfactant in experimental transplantation preserves graft hemodynamics and alveolar morphology. Exp Biol Med (Maywood) 2003; 228:540.
  74. Kermeen FD, McNeil KD, Fraser JF, et al. Resolution of severe ischemia-reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J Heart Lung Transplant 2007; 26:850.
  75. Amital, A, Shitrit, D, Raviv, Y, et al. The use of surfactant in lung transplantation: A randomized control pilot study. J Heart Lung Transplant 2006; 25 Suppl 2:S49.
  76. Strüber M, Fischer S, Niedermeyer J, et al. Effects of exogenous surfactant instillation in clinical lung transplantation: a prospective, randomized trial. J Thorac Cardiovasc Surg 2007; 133:1620.
  77. Pierre AF, Xavier AM, Liu M, et al. Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function. Transplantation 1998; 66:723.
  78. Keshavjee S, Davis RD, Zamora MR, et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 2005; 129:423.
  79. Wittwer T, Grote M, Oppelt P, et al. Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. J Heart Lung Transplant 2001; 20:358.
  80. Ishiyama T, Dharmarajan S, Hayama M, et al. Inhibition of nuclear factor kappaB by IkappaB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Thorac Cardiovasc Surg 2005; 130:194.
  81. Tagawa T, Dharmarajan S, Hayama M, et al. Endobronchial gene transfer of soluble type I interleukin-1 receptor ameliorates lung graft ischemia-reperfusion injury. Ann Thorac Surg 2004; 78:1932.
  82. Martins S, de Perrot M, Imai Y, et al. Transbronchial administration of adenoviral-mediated interleukin-10 gene to the donor improves function in a pig lung transplant model. Gene Ther 2004; 11:1786.
  83. Fedalen PA, Piacentino V 3rd, Jeevanandam V, et al. Pharmacologic pre-conditioning and controlled reperfusion prevent ischemia-reperfusion injury after 30 minutes of hypoxia/ischemia in porcine hearts. J Heart Lung Transplant 2003; 22:1234.
  84. Otterbein LE, Choi AM. Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol 2000; 279:L1029.
  85. Aigner C, Jaksch P, Taghavi S, et al. Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant 2008; 27:60.
  86. Prekker ME, Nath DS, Walker AR, et al. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2006; 25:371.
  87. Suzuki Y, Cantu E, Christie JD. Primary graft dysfunction. Semin Respir Crit Care Med 2013; 34:305.
  88. Fiser SM, Tribble CG, Long SM, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73:1041.
  89. Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007; 26:1004.
  90. Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175:507.
  91. Bharat A, Kuo E, Steward N, et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008; 86:189.
  92. Fisher AJ, Wardle J, Dark JH, Corris PA. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2002; 21:1206.
  93. Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007; 83:150.